Skip to search formSkip to main contentSkip to account menu

Elacridar

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
This study was designed to investigate the effects of P-glycoprotein (P-gp) expressed in the intestine on the nonlinear… 
2014
2014
In the past years, the development of oral formulations of the taxane anticancer drugs paclitaxel (Taxol®) and docetaxel… 
2013
2013
Tariquidar and elacridar are among the most potent inhibitors of the multidrug resistance transporter P‐glycoprotein (P‐gp), but… 
2012
2012
Although the CB1 receptor antagonist/inverse agonist rimonabant has positive effects on weight loss and cardiometabolic risk… 
2011
2011
P-glycoprotein (P-gp) is involved in MDR and in neurodegenerative disorders such as Parkinson disease (PD), Alzheimer disease (AD… 
2008
2008
textabstractImatinib mesylate, the first tyrosine kinase inhibitor to gain approval by the FDA, remains as a pivotal example of…